Medilytic Biomedicals Profile
Key Indicators
- Authorised Capital ₹ 0.90 M
as on 05-07-2024
- Paid Up Capital ₹ 0.21 M
as on 05-07-2024
- Company Age 3 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 M
as on 05-07-2024
About Medilytic Biomedicals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.90 M and a paid-up capital of Rs 0.21 M.
The company currently has active open charges totaling ₹1.00 M.
Pankaj Tripathi, Anurag Das, and Siddharth Saksena serve as directors at the Company.
- CIN/LLPIN
U24100UP2021PTC149728
- Company No.
149728
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Medilytic Biomedicals Private Limited offer?
Medilytic Biomedicals Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, IVDs & Analyzers, Flavours & Aromatics, Food Enzymes, Clinical Reagents, Biochemistry Analyzer, Hematology Analyzers, Rapid Test Kit.
Who are the key members and board of directors at Medilytic Biomedicals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Siddharth Saksena  | Director | 29-Jul-2021 | Current |
| Anurag Das | Director | 29-Jul-2021 | Current |
| Pankaj Tripathi | Director | 29-Jul-2021 | Current |
Financial Performance of Medilytic Biomedicals.
Enhance accessibility to Medilytic Biomedicals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Medilytic Biomedicals?
Unlock access to Medilytic Biomedicals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 Apr 2023 | ₹1.00 M | Open |
How Many Employees Work at Medilytic Biomedicals?
Medilytic Biomedicals has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medilytic Biomedicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medilytic Biomedicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
